Bafna Pharmaceuticals surges on obtaining product approval from Ghana FDA

03 May 2013 Evaluate

Bafna Pharmaceuticals is currently trading at Rs. 38.00, up by 0.40 points or 1.06% from its previous closing of Rs. 37.60 on the BSE.

The scrip opened at Rs. 37.30 and has touched a high and low of Rs. 38.60 and Rs. 37.30 respectively. So far 27152 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 52.25 on 25-May-2012 and a 52 week low of Rs. 33.40 on 18-Mar-2013.

Last one week high and low of the scrip stood at Rs. 38.90 and Rs. 36.85 respectively. The current market cap of the company is Rs. 70.52 crore.

The promoters holding in the company stood at 37.37% while Non-Institutions held 62.63%.

Bafna Pharmaceuticals, a Chennai-based Pharma company, received approval from Ghana Food and Drug Administration (FDA) to market Omeran-20 capsules (Gastro - Resistant Omeprazole Capsules 20mg) , a proton pump inhibitor used in the treatment of reflux oesophagitis, peptic ulcer disease (PUD), Gastroesophageal reflux disease (GORD/GERD) and Zollinger-Ellison syndrome. With this, Bafna now has 15 number of formulation approvals from Ghana FDA for products of the company.

Bafna Pharmaceutical is a Chennai-based Pharma company engaged in the manufacturing of pharmaceutical formulations of Betalactum and Non-Betalactum.  The company has 173 products registered in UK, Sri Lanka, Nepal, Ukraine, Ghana, Ethiopia, Philippines, Kryghistan, Georgia, Honduras, Colombia, Uzbekhistan, Vietnam and Nigeria.

Bafna Pharma Share Price

85.54 -4.50 (-5.00%)
03-Jun-2024 13:48 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1462.15
Dr. Reddys Lab 5796.05
Cipla 1449.30
Zydus Lifesciences 1028.20
Lupin 1584.10
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.